227 related articles for article (PubMed ID: 32883368)
1. A protein interaction map identifies existing drugs targeting SARS-CoV-2.
Cava C; Bertoli G; Castiglioni I
BMC Pharmacol Toxicol; 2020 Sep; 21(1):65. PubMed ID: 32883368
[TBL] [Abstract][Full Text] [Related]
2. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal.
Fantini J; Chahinian H; Yahi N
Int J Antimicrob Agents; 2020 Aug; 56(2):106020. PubMed ID: 32405156
[TBL] [Abstract][Full Text] [Related]
3. Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19.
Cheng H; Wang Y; Wang GQ
J Med Virol; 2020 Jul; 92(7):726-730. PubMed ID: 32221983
[TBL] [Abstract][Full Text] [Related]
4. Drugs targeting various stages of the SARS-CoV-2 life cycle: Exploring promising drugs for the treatment of Covid-19.
Poduri R; Joshi G; Jagadeesh G
Cell Signal; 2020 Oct; 74():109721. PubMed ID: 32711111
[TBL] [Abstract][Full Text] [Related]
5. In Silico Discovery of Candidate Drugs against Covid-19.
Cava C; Bertoli G; Castiglioni I
Viruses; 2020 Apr; 12(4):. PubMed ID: 32268515
[TBL] [Abstract][Full Text] [Related]
6. A molecular docking study revealed that synthetic peptides induced conformational changes in the structure of SARS-CoV-2 spike glycoprotein, disrupting the interaction with human ACE2 receptor.
Souza PFN; Lopes FES; Amaral JL; Freitas CDT; Oliveira JTA
Int J Biol Macromol; 2020 Dec; 164():66-76. PubMed ID: 32693122
[TBL] [Abstract][Full Text] [Related]
7. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
[TBL] [Abstract][Full Text] [Related]
8. COVID-19 Coronavirus spike protein analysis for synthetic vaccines, a peptidomimetic antagonist, and therapeutic drugs, and analysis of a proposed achilles' heel conserved region to minimize probability of escape mutations and drug resistance.
Robson B
Comput Biol Med; 2020 Jun; 121():103749. PubMed ID: 32568687
[TBL] [Abstract][Full Text] [Related]
9. A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures.
Dinnon KH; Leist SR; Schäfer A; Edwards CE; Martinez DR; Montgomery SA; West A; Yount BL; Hou YJ; Adams LE; Gully KL; Brown AJ; Huang E; Bryant MD; Choong IC; Glenn JS; Gralinski LE; Sheahan TP; Baric RS
Nature; 2020 Oct; 586(7830):560-566. PubMed ID: 32854108
[TBL] [Abstract][Full Text] [Related]
10. Identification of SARS-CoV-2 Cell Entry Inhibitors by Drug Repurposing Using
Choudhary S; Malik YS; Tomar S
Front Immunol; 2020; 11():1664. PubMed ID: 32754161
[TBL] [Abstract][Full Text] [Related]
11. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
Gordon DE; Jang GM; Bouhaddou M; Xu J; Obernier K; White KM; O'Meara MJ; Rezelj VV; Guo JZ; Swaney DL; Tummino TA; Hüttenhain R; Kaake RM; Richards AL; Tutuncuoglu B; Foussard H; Batra J; Haas K; Modak M; Kim M; Haas P; Polacco BJ; Braberg H; Fabius JM; Eckhardt M; Soucheray M; Bennett MJ; Cakir M; McGregor MJ; Li Q; Meyer B; Roesch F; Vallet T; Mac Kain A; Miorin L; Moreno E; Naing ZZC; Zhou Y; Peng S; Shi Y; Zhang Z; Shen W; Kirby IT; Melnyk JE; Chorba JS; Lou K; Dai SA; Barrio-Hernandez I; Memon D; Hernandez-Armenta C; Lyu J; Mathy CJP; Perica T; Pilla KB; Ganesan SJ; Saltzberg DJ; Rakesh R; Liu X; Rosenthal SB; Calviello L; Venkataramanan S; Liboy-Lugo J; Lin Y; Huang XP; Liu Y; Wankowicz SA; Bohn M; Safari M; Ugur FS; Koh C; Savar NS; Tran QD; Shengjuler D; Fletcher SJ; O'Neal MC; Cai Y; Chang JCJ; Broadhurst DJ; Klippsten S; Sharp PP; Wenzell NA; Kuzuoglu-Ozturk D; Wang HY; Trenker R; Young JM; Cavero DA; Hiatt J; Roth TL; Rathore U; Subramanian A; Noack J; Hubert M; Stroud RM; Frankel AD; Rosenberg OS; Verba KA; Agard DA; Ott M; Emerman M; Jura N; von Zastrow M; Verdin E; Ashworth A; Schwartz O; d'Enfert C; Mukherjee S; Jacobson M; Malik HS; Fujimori DG; Ideker T; Craik CS; Floor SN; Fraser JS; Gross JD; Sali A; Roth BL; Ruggero D; Taunton J; Kortemme T; Beltrao P; Vignuzzi M; García-Sastre A; Shokat KM; Shoichet BK; Krogan NJ
Nature; 2020 Jul; 583(7816):459-468. PubMed ID: 32353859
[TBL] [Abstract][Full Text] [Related]
12. Scaffold morphing of arbidol (umifenovir) in search of multi-targeting therapy halting the interaction of SARS-CoV-2 with ACE2 and other proteases involved in COVID-19.
Choudhary S; Silakari O
Virus Res; 2020 Nov; 289():198146. PubMed ID: 32866534
[TBL] [Abstract][Full Text] [Related]
13. In silico ADMET and molecular docking study on searching potential inhibitors from limonoids and triterpenoids for COVID-19.
Vardhan S; Sahoo SK
Comput Biol Med; 2020 Sep; 124():103936. PubMed ID: 32738628
[TBL] [Abstract][Full Text] [Related]
14. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
[TBL] [Abstract][Full Text] [Related]
15. Prioritizing potential ACE2 inhibitors in the COVID-19 pandemic: Insights from a molecular mechanics-assisted structure-based virtual screening experiment.
Teralı K; Baddal B; Gülcan HO
J Mol Graph Model; 2020 Nov; 100():107697. PubMed ID: 32739642
[TBL] [Abstract][Full Text] [Related]
16. Purposing Saikosaponins for the treatment of COVID-19.
Bahbah EI; Negida A; Nabet MS
Med Hypotheses; 2020 Jul; 140():109782. PubMed ID: 32353743
[No Abstract] [Full Text] [Related]
17. Natural Flavonoids as Potential Angiotensin-Converting Enzyme 2 Inhibitors for Anti-SARS-CoV-2.
Muchtaridi M; Fauzi M; Khairul Ikram NK; Mohd Gazzali A; Wahab HA
Molecules; 2020 Sep; 25(17):. PubMed ID: 32882868
[TBL] [Abstract][Full Text] [Related]
18. Identification of a repurposed drug as an inhibitor of Spike protein of human coronavirus SARS-CoV-2 by computational methods.
Unni S; Aouti S; Thiyagarajan S; Padmanabhan B
J Biosci; 2020; 45(1):. PubMed ID: 33184246
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin converting enzyme-2 as therapeutic target in COVID-19.
Roshanravan N; Ghaffari S; Hedayati M
Diabetes Metab Syndr; 2020; 14(4):637-639. PubMed ID: 32428864
[TBL] [Abstract][Full Text] [Related]
20. Novel Drugs Targeting the SARS-CoV-2/COVID-19 Machinery.
Sternberg A; McKee DL; Naujokat C
Curr Top Med Chem; 2020; 20(16):1423-1433. PubMed ID: 32416679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
